The POCD is defined as changes in a patient’s mental activity, social activity, personality, and cognitive abilities after they were anesthetized or underwent surgery (
26). The POCD is regarded as a major postoperative neurological complication that occurs in older individuals (
27). The presentations of POCD include impaired attention, memory, language comprehension, and decreased social skills (
28).
Inhalation anesthesia is linked to a higher incidence of POCD than intravenous anesthesia (
29). Sevoflurane has become a first-line inhalation anesthetic among inhalation anesthetics due to its advantages of quick induction, moderate irritation, quick recovery, and stability maintenance (
30,
31). Therefore, sevoflurane-induced cognitive dysfunction has become the focus of POCD research. The mechanism via which sevoflurane triggers POCD is observed to be closely linked to neuroinflammation and apoptosis (
32). Therefore, understanding the mechanisms of sevoflurane-induced POCD and comprehending suitable targets and mechanisms to reduce or eliminate the occurrence of cognitive dysfunction is challenging. In this study, it was shown that melatonin could significantly improve the sevoflurane-induced cognitive impairment noted in elderly mice and attenuate the increase in autophagic proteins in the hippocampus, inhibiting neuronal apoptosis and neuroinflammation.
Melatonin is an indole neuroendocrine hormone with a wide range of biological activities (
16) widely distributed in the human body. Melatonin’s secretion is regulated by the circadian rhythm in the suprachiasmatic nucleus of the hypothalamus. Melatonin can act on various systems in the body via multiple pathways and targets, has strong anti-inflammatory, anti-apoptotic, and anti-oxidative effects, and exerts neuroprotective effects. Studies have revealed that melatonin can improve chemical-induced brain damage by inhibiting oxidative stress, apoptosis, and autophagic mechanisms (
33). The results of a large-sample, multicenter, controlled, randomized, and double-blind trial of elderly patients who underwent hip surgery (
34) revealed that exogenous melatonin administration for 5 consecutive days significantly reduced the incidence rate of delirium 8 days after admission.
In this study, it was noted that the elderly mice experienced severe POCD after anesthesia with 2% sevoflurane, which caused a loss of cognitive function. The aforementioned results are consistent with the results of a previous study (
35). However, aged mice showed improved cognitive function after treatment with melatonin, which was observed during the Morris water maze test. In comparison to the S-group mice, the S + M mice showed more platform crossings and achieved the target quadrant swimming time and distance. This finding indicates that melatonin can significantly reduce cognitive dysfunction induced by sevoflurane in aged mice. However, previous studies have also shown that the aging brain shows selective neurochemical changes involving several neuronal cell groups, and melatonin levels decrease during aging.
In the mouse model of Alzheimer’s disease, the elevation of brain melatonin significantly reduced the level of potentially toxic Aβ peptide. Exogenous compensation for melatonin loss during aging can promote central nervous system function by reducing metal-induced toxicity, lipid peroxidation, and cholinergic signal transduction loss. Therefore, whether exogenous melatonin supplementation can directly affect the cognitive function of aged mice through the above-mentioned mechanism still needs further exploration.
The activation of the anti-apoptotic effector Akt by PI3K can help promote cell survival (
36). In most cases, the PI3K/Akt pathway transmits pro-survival signals in several cell types (
37). Earlier studies highlighted that when rats were exposed to varying sevoflurane concentrations (e.g., 1.5% and 3%), it significantly elevated the level of pro-inflammatory factors (e.g., IL-8, IL-6, and tumor necrosis factor-α (TNF-α)) in the hippocampus of the rats. The experimental results also showed that the expression of the PI3K-Akt pathway-related factors was significantly inhibited, and dexmedetomidine treatment could suppress the inactivation of the pathway; however, this effect could be inhibited by YL294002 (i.e., the inhibitor of PI3K/Akt pathway) (
38).
In this study, the findings showed that the 2% sevoflurane exposure inactivated the hippocampal PI3K/Akt/mTOR signaling pathway in mice, and this process was reversed by melatonin. The therapeutic effect of melatonin was partially reversed when combined with YL294002 and rapamycin (i.e., an mTOR inhibitor). The aforementioned results suggest that melatonin might improve POCD symptoms in mice via the PI3K/Akt/mTOR signaling pathway. In addition, earlier studies revealed that the hippocampal PI3K/Akt/mTOR signaling pathway negatively regulates autophagy-linked proteins; therefore, the downstream expression of autophagic proteins was further explored. The Western blotting results confirmed that melatonin could also inhibit 2% sevoflurane-induced autophagic activation in the mouse hippocampus by regulating the hippocampal PI3K/Akt/mTOR signaling pathway.
Neurons in the hippocampal region of the brain are critical cells for learning and memory (
39). Neuronal apoptosis is considered a direct factor in POCD onset and advancement (
40). Sevoflurane-induced neuronal apoptosis leads to cognitive impairment in rats (
41). The caspase cascade is a vital component of apoptosis (
42). A previous study has revealed that melatonin can alleviate secondary brain injury induced by cerebral hemorrhage in rats by inhibiting neuronal apoptosis (
43). Therefore, the effect of melatonin on the mouse hippocampal neuronal apoptosis pathway was examined in this study. The findings of these experiments revealed that 2% sevoflurane significantly induced the up-regulation of Bax and cleaved caspase-3 (apoptotic proteins) and down-regulation of Bcl-2 (anti-apoptotic protein) in the hippocampus, accompanied by chromatin condensation and nuclear pyknosis, cell damage, and increased apoptosis. This phenomenon was significantly reversed by melatonin, signifying that melatonin exerted a protective effect against sevoflurane-induced nerve damage.
Neuroinflammation, particularly in the hippocampus, significantly contributes to POCD progression, mainly due to cytokines produced by the immune cells of the central nervous system (
39,
44). It is widely accepted that activated microglia, which are important mediators of neuroinflammation, release pro-inflammatory cytokines in the hippocampus (
45). High pro-inflammatory cytokine levels enhance excitotoxicity and lead to memory impairment. Previous studies have shown that sevoflurane anesthesia can significantly induce the up-regulation of IL-6, TNF-α, IL-1β, and iNOS expression in the hippocampus of aged rodents (
46,
47). The inhibition of cytokines has been shown to effectively alleviate POCD (
39). Therefore, the effect of melatonin on neuroinflammation was investigated in this study. The results indicated that melatonin could also inhibit sevoflurane-induced microglial activation in the hippocampus and the secretion of related inflammatory factors. A previous study has also reported that melatonin can ultimately reduce neuroinflammation by inhibiting lipopolysaccharide-stimulated microglial activation (
48).
5.1. Conclusions
In conclusion, the open field and Morris water maze tests showed that melatonin significantly reduced neurological dysfunction in sevoflurane-anesthetized aged mice. The molecular experiment results suggest that this neuroprotective effect might be related to the restoration of sevoflurane-induced down-regulated PI3K/Akt/mTOR expression by melatonin treatment and the significant reduction of sevoflurane-induced apoptosis and neuroinflammation. This finding highlights the value of melatonin in the treatment of cognitive dysfunction and might provide a new strategy and basis for clinical drug treatment.